Quintiles' PGx Focus Continues with London Genetics Personalized Medicine Alliance | GenomeWeb

By Turna Ray

Announcing its third
personalized medicine pact this month, biopharmaceutical services provider Quintiles has jumped head-first into the genomically guided drug development space.

This week, Quintiles announced it would collaborate with pharmacogenetics firm London Genetics to provide personalized medicine services to drug developers. Financial terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.